Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson's disease

Quantitative magnetic resonance imaging is a promising in vivo imaging technique revealing insights into different aspects of brain morphology in neurodegenerative diseases based on the determination of physical tissue parameters. Using combined T1- and T2*-mapping, we investigated changes of local relaxation times in the midbrain and lower brainstem of 20 patients with early Parkinson's disease (PD) compared to 20 healthy controls. Voxelwise statistical parametric mapping disclosed a widespread reduction of midbrain T1 values contralateral to the clinically more severely affected limbs. Within the SN, the T1 decrease matched the known pattern of selective neuronal loss as examined in various post-mortem studies, suggesting that T1 is a marker for PD related tissue pathology. However, the spatial extent of T1 reductions exceeded the SN and reached non-dopaminergic areas in the pontomesencephalic junction potentially involved in early non-motor symptoms of PD. In contrast, T2*-mapping revealed a bilateral decrease of T2* values restricted to the SN, indicating a local increase in total iron content. We conclude that, particularly in longitudinal studies, quantitative T1 may be a valuable marker for the monitoring of progressive neuronal loss in PD, whereas nigral T2* reductions might be more closely associated with an increased general vulnerability for the development of the disorder.

[1]  D J Brooks,et al.  Clinical and [18F] dopa PET findings in early Parkinson's disease. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[2]  Martyn N J Paley,et al.  MRI assessment of basal ganglia iron deposition in Parkinson's disease , 2008, Journal of magnetic resonance imaging : JMRI.

[3]  David N. Kennedy,et al.  Automated Brainstem Co-registration (ABC) for MRI , 2006, NeuroImage.

[4]  V. Uversky,et al.  Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. , 2001, The Journal of biological chemistry.

[5]  David J. Brooks,et al.  A comparison of 18F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson’s disease , 2001, Neurology.

[6]  Makoto Sawada,et al.  Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains , 2003, Acta Neuropathologica.

[7]  Simon B. Eickhoff,et al.  A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data , 2005, NeuroImage.

[8]  R. Djaldetti,et al.  The mystery of motor asymmetry in Parkinson's disease , 2006, The Lancet Neurology.

[9]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[10]  N. Gelman,et al.  Interregional variation of longitudinal relaxation rates in human brain at 3.0 T: Relation to estimated iron and water contents , 2001, Magnetic resonance in medicine.

[11]  M. Graeber,et al.  Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration , 2006, Acta Neuropathologica.

[12]  M. Hariz,et al.  Stereotactic localization of the human pedunculopontine nucleus: atlas-based coordinates and validation of a magnetic resonance imaging protocol for direct localization. , 2008, Brain : a journal of neurology.

[13]  R. Turner,et al.  Does Hypercapnia-Induced Cerebral Vasodilation Modulate the Hemodynamic Response to Neural Activation? , 2001, NeuroImage.

[14]  K. Ray Chaudhuri,et al.  Early Parkinson’s disease and non-motor issues , 2008, Journal of Neurology.

[15]  Helmut Heinsen,et al.  Brainstem pathology and non-motor symptoms in PD , 2010, Journal of the Neurological Sciences.

[16]  P. Mcgeer,et al.  Glial reactions in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[17]  N. Pelc,et al.  Brain motion: measurement with phase-contrast MR imaging. , 1992, Radiology.

[18]  W. Gibb,et al.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[19]  S. Kollias,et al.  Duvernoy's Atlas of the Human Brain Stem and Cerebellum , 2009 .

[20]  S. Holland,et al.  NMR relaxation times in the human brain at 3.0 tesla , 1999, Journal of magnetic resonance imaging : JMRI.

[21]  Yoshiharu Tamakawa,et al.  The substantia nigra in Parkinson disease: proton density-weighted spin-echo and fast short inversion time inversion-recovery MR findings. , 2002, AJNR. American journal of neuroradiology.

[22]  Werner Jaschke,et al.  Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. , 2006, Brain : a journal of neurology.

[23]  R. Ordidge,et al.  Increased iron‐related MRI contrast in the substantia nigra in Parkinson's disease , 1995, Neurology.

[24]  E. S. Watkins,et al.  Stereotaxic atlas of the human brainstem and cerebellar nuclei : a variability study , 1978 .

[25]  Peter Riederer,et al.  The relevance of iron in the pathogenesis of Parkinson’s disease , 2011, Journal of neurochemistry.

[26]  M Hutchinson,et al.  Parkinson's disease: a novel MRI method for determining structural changes in the substantia nigra , 1999, Journal of neurology, neurosurgery, and psychiatry.

[27]  Daniela Berg,et al.  Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. , 2002, Archives of neurology.

[28]  T. Foster,et al.  A review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1-100 MHz: dependence on tissue type, NMR frequency, temperature, species, excision, and age. , 1984, Medical physics.

[29]  R. Ordidge,et al.  Assessment of relative brain iron concentrations using T2‐weighted and T2*‐weighted MRI at 3 Tesla , 1994, Magnetic resonance in medicine.

[30]  D. J. Brooks,et al.  Morphological and functional imaging studies on the diagnosis and progression of Parkinson’s disease , 2000, Journal of Neurology.

[31]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[32]  J V Hajnal,et al.  A comparison of (18)F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease. , 2001, Neurology.

[33]  Stephen D. Mayhew,et al.  Brainstem functional magnetic resonance imaging: Disentangling signal from physiological noise , 2008, Journal of magnetic resonance imaging : JMRI.

[34]  Marguerite Wieler,et al.  Midbrain iron content in early Parkinson disease , 2008, Neurology.

[35]  Alexander Gerhard,et al.  In vivo imaging of microglial activation with [11C](R)‐PK11195 PET in corticobasal degeneration , 2004, Movement disorders : official journal of the Movement Disorder Society.

[36]  Thomas E. Nichols,et al.  Nonparametric permutation tests for functional neuroimaging: A primer with examples , 2002, Human brain mapping.

[37]  P D Griffiths,et al.  Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. , 2000, Brain : a journal of neurology.

[38]  Paul M. Matthews,et al.  MRI characteristics of the substantia nigra in Parkinson's disease: A combined quantitative T1 and DTI study , 2009, NeuroImage.

[39]  J Fiehler,et al.  Age-Dependent Normal Values of T2* and T2′ in Brain Parenchyma , 2008, American Journal of Neuroradiology.

[40]  M Hutchinson,et al.  Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging. , 2000, AJNR. American journal of neuroradiology.

[41]  M. Hoehn,et al.  Parkinsonism , 1967, Neurology.

[42]  T. Peters,et al.  High‐resolution T1 and T2 mapping of the brain in a clinically acceptable time with DESPOT1 and DESPOT2 , 2005, Magnetic resonance in medicine.

[43]  D. Yarnitsky,et al.  Quantitative measurement of pain sensation in patients with Parkinson disease , 2004, Neurology.

[44]  R. Deichmann,et al.  Influence of RF spoiling on the stability and accuracy of T1 mapping based on spoiled FLASH with varying flip angles , 2009, Magnetic resonance in medicine.

[45]  Daniela Berg,et al.  Five‐year follow‐up study of hyperechogenicity of the substantia nigra in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[46]  Michael Hutchinson,et al.  On false negatives in MRI studies of Parkinson disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[47]  A. Graybiel,et al.  The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.

[48]  K. Chaudhuri,et al.  Non-motor symptoms of Parkinson's disease: diagnosis and management , 2006, The Lancet Neurology.

[49]  P Riederer,et al.  Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains , 1991, Journal of neurochemistry.

[50]  Klaus Seppi,et al.  An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism , 2005, Current opinion in neurology.

[51]  Daniela Berg,et al.  Iron metabolism in Parkinsonian syndromes , 2006, Movement disorders : official journal of the Movement Disorder Society.

[52]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[53]  Michael Hutchinson,et al.  Detection of Parkinson's disease by MRI: Spin‐lattice distribution imaging , 2008, Movement disorders : official journal of the Movement Disorder Society.

[54]  Karl J. Friston Testing for anatomically specified regional effects , 1997, Human brain mapping.

[55]  R. Hauser,et al.  Prevalence and treatment of non-motor symptoms in Parkinson's disease. , 2007, Parkinsonism & related disorders.

[56]  A J Lees,et al.  Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[57]  L. Bongiovanni,et al.  Sympathetic skin response asymmetry in early stage idiopathic Parkinson's disease , 1999, Clinical Neurophysiology.

[58]  Kiyoshi Morita,et al.  Clinical significance of T1-weighted MR images following transient cerebral ischemia , 2006, Journal of the Neurological Sciences.

[59]  M. B. Spraker,et al.  High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease , 2009, Neurology.

[60]  Vasily L Yarnykh,et al.  Actual flip‐angle imaging in the pulsed steady state: A method for rapid three‐dimensional mapping of the transmitted radiofrequency field , 2007, Magnetic resonance in medicine.

[61]  Christine Preibisch,et al.  Rapid single‐scan T  2* ‐mapping using exponential excitation pulses and image‐based correction for linear background gradients , 2009, Magnetic resonance in medicine.

[62]  H Bratzke,et al.  Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. , 1998, Progress in brain research.

[63]  C D Marsden,et al.  Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.

[64]  Christine Preibisch,et al.  Exponential excitation pulses for improved water content mapping in the presence of background gradients , 2008, Magnetic resonance in medicine.

[65]  R. Brooks,et al.  T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: relation to iron content. , 1999, Radiology.

[66]  P. Riederer,et al.  Crosslinking of α-synuclein by advanced glycation endproducts — an early pathophysiological step in Lewy body formation? , 2000, Journal of Chemical Neuroanatomy.

[67]  David Eidelberg,et al.  Dissociation of Metabolic and Neurovascular Responses to Levodopa in the Treatment of Parkinson's Disease , 2008, The Journal of Neuroscience.